Heitzeneder et al. reported a strategy to enhance GPC2-CAR efficacy against low-antigen-density neuroblastoma by engineering the transmembrane and co-stimulatory domains and overexpressing c-Jun.12 Here, GPC2 is linked to neuroblastoma.